Go to Top

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer.

Clinical Trials

Current Clinical Trials

Seviteronel Clinical Development Studies 

Seviteronel is in Phase 2 clinical development for both breast and prostate cancer.  Patients are joining the studies at clinics and major medical centers across the United States.  If you, a loved one, or someone you know are interested in participating in one of the studies described below, and would like more information, please contact Lisa Franklin at:  919-695-9493.

Breast Cancer Clinical Studies

Study 006: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer

Currently enrolling men with breast cancer and women with triple-negative breast cancer.

https://clinicaltrials.gov/ct2/show/NCT02580448

Prostate Cancer Clinical Studies

Study 001: A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Patients with Castration-Resistant Prostate Cancer.

Currently enrolling men with castration-resistant prostate cancer who were previously treated with abiraterone or enzalutamide.

http://clinicaltrials.gov/ct2/show/NCT02012920

Study 002: A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients with Metastatic Castration Resistant Prostrate Cancer Who Have Previously Been Treated With Enzalutamide

Currently enrolling men with castration-resistant prostate cancer who were previously treated with enzalutamide.

http://clinicaltrials.gov/ct2/show/NCT02130700

Study 003: A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Once-Daily Oral VT-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone

Currently enrolling men with castration-resistant prostate cancer who were previously treated with abiraterone or enzalutamide.

https://clinicaltrials.gov/ct2/show/NCT02445976

Study 004: A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Once-Daily VT-464 in Patients with Castration-Resistant Prostate Cancer.

Enrollment for the study is complete.

https://clinicaltrials.gov/ct2/show/NCT02361086